يعرض 1 - 10 نتائج من 18 نتيجة بحث عن '"ХОЛЕСТЕРИН ЛИПОПРОТЕИНОВ ВЫСОКОЙ ПЛОТНОСТИ"', وقت الاستعلام: 1.31s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: The study was performed with the support of the National Medical Research Center of Cardiology., Исследование проведено при поддержке Национального медицинского исследовательского центра кардиологии.

    المصدر: Rational Pharmacotherapy in Cardiology; Vol 17, No 6 (2021); 867-872 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 6 (2021); 867-872 ; 2225-3653 ; 1819-6446

    وصف الملف: application/pdf

    العلاقة: https://www.rpcardio.com/jour/article/view/2632/2265Test; Powell-Wiley Т, Poirier P, Burke L, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984-1010. DOI:10.1161/CIR.0000000000000973.; Neeland IJ, Poirier P, Després JP. Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management. Circulation. 2018;137(13):1391-406. DOI:10.1161/CIR-CULATIONAHA.117.029617.; Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715-25. DOI:10.1016/S2213-8587(19)30084-1.; Omura-Ohata Y, Son C, Makino H, et. al. Efficacy of visceral fat estimation by dual bioelectrical impedance analysis in detecting cardiovascular risk factors in patients with type 2 diabetes. Cardiovasc Diabetol. 2019;18(1):137. DOI:10.1186/s12933-019-0941-y.; Окороков П.Л., Васюкова О.В., Воронцов А.В. Методы оценки количества и распределения жировой ткани в организме и их клиническое значение. Проблемы Эндокринологии. 2014;60(3):53-8. DOI:10.14341/probl201460353-58.; Body composition analyzer/body fat analyzer and calorie tracker. Section 6.1 Stayhealthy BC1 and Stayhealthy/Fitness Expert BC2, Body composition analyzer 510K submission [cited 2020 Jun 20]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf5/K052522.pdfTest.; Romero-Corral A, Somers VK, Sierra-Johnson J, et al. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J. 2010;31(6):737-46. DOI:10.1093/eurheartj/ehp487.; Jung CH, Lee WJ, Song K. Metabolically healthy obesity: a friend or foe? Korean J Intern Med. 2017;32(4):611-21. DOI:10.3904/kjim.2016.259.; Dhana K, Koolhaas CM, van Rossum E, et al. Metabolically Healthy Obesity and the Risk of Cardiovascular Disease in the Elderly Population. PLoS One. 2016;11(4):e0154273. DOI:10.1371/journal.pone.0154273.; Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5. DOI:10.1161/CIRCULATIONAHA.109.192644.; Fruh SM. Obesity: Risk factors, complications, and strategies for sustainable long-term weight management. J Am Assoc Nurse Pract. 2017;29(S1):S3-S14. DOI:10.1002/2327-6924.12510.; Ozhan H, Alemdar R, Caglar O, et al. MELEN Investigators. Performance of bioelectrical impedance analysis in the diagnosis of metabolic syndrome. J Investig Med. 2012;60(3):587-91. DOI:10.2310/JIM.0b013e318244e2d9.; Rodríguez AS, Soidán JG, Gómez JA, et al. Metabolic syndrome and visceral fat in women with cardiovascular risk factor. Nutr Hosp. 2017;34(4):863-8. DOI:10.20960/nh.1085.; National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421. DOI:10.1161/circ.106.25.3143.; Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-52. DOI:10.1161/CIRCULATIONAHA.105.169404.; Iacobellis G, Assael F, Ribaudo MC, et al. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res. 2003;11(2):304-10. DOI:10.1038/oby.2003.45.; Oliverosa E, Somersa VK, Sochor O, et al. The Concept of Normal Weight Obesity. Prog Cardiovasc Dis. 2014;56(4):4260-33. DOI:10.1016/j.pcad.2013.10.003.; Tchernof A, Després JP. Pathophysiology of Human Visceral Obesity: An Update. Physiol Rev. 2013;93(1):359-404. DOI:10.1152/physrev.00033.2011.; Миклишанская С.В., Золозова Е.А., Сафиуллина А.А., Мазур Н.А. Висцеральное ожирение у больных с различными индексами массы тела. Лечащий Врач. 2020;(8):66-70. DOI:10.26295/OS.2020.19.39.011.; Миклишанская С.В., Саидова М.А., Орловский А.А., Сычев А.В., и др. Различия в накоплении висцеральной и эпикардиальной жировой ткани у больных с ишемической болезнью сердца и без нее. Русский Медицинский Журнал. 2021;(2):13-7.; Миклишанская С.В., Золозова Е.А., Орловский А.А., и др. Обоснование необходимости создания новой классификации ожирения. Лечащий Врач. 2021;(7):58-62. DOI:10.51793/OS.2021.24.7.011.; https://www.rpcardio.com/jour/article/view/2632Test

  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية

    المصدر: Rational Pharmacotherapy in Cardiology; Vol 10, No 5 (2014); 540-547 ; Рациональная Фармакотерапия в Кардиологии; Vol 10, No 5 (2014); 540-547 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2014-10-5

    وصف الملف: application/pdf

    العلاقة: https://www.rpcardio.com/jour/article/view/215/225Test; ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217S :S1-S44.; Еuropean guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14 Suppl 2:E1-40.; Pencina M.J., Agostino R.B., Larson S.M. Predicting the 30-Year Risk of cardiovascular disease: The Framingham Heart Study. Circulation 2009;119:3078-84.; Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010;35(2):139-51.; Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract 2005;59(2):239-52.; Chang S.M., Yasbek N., Lakks N.M. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv 2004;62:193-7.; Patti G., Pasceri V., Colonna G., et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Results of the ARMYDAACS Randomized Trial. J Am Coll Cardiol 2007;49:1272-8.; Di Sciascio G., Patti G., Pasceri V., et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009;54;558-65.; RSC, NSA, RSCR expert opinion to optimize of statin therapy in clinical practice. Ration Pharmacother Cardiol 2011; 7 (1): 107-9. Russian (Заключение экспертов ВНОК, НОА и РОСОКР по оптимиза-ции терапии статинами в клинической практике. Рациональная Фармакотерапия в Кардиологии 2011; 7(1):107-9).; Lablanchea J.M., Leoneb A., Merkelyc B., et al. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein AI ratio in patients with acute coronary syndrome: Results of the CENTAURUS study. Arch Cardiovasc Dis 2010; 103:160-9.; Zadionchenko VS, Shehyan GG, Shahray NB, et al. Effect of rosuvastatin on lipid metabolism, microcirculation and central hemodynamics in patients with acute coronary syndrome. Consilium Medicum 2011; 13 (5): 4-8. Russian (Задионченко В.С., Шехян Г.Г., Шахрай Н.Б. и др. Влияние розува-статина на липидный обмен, микроциркуляцию и показатели центральной гемодинамики у боль-ных с острым коронарным синдромом. Consilium Medicum 2011;13(5):4-8).; Otagiri К., Tsutsui H., Kumazaki S. Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome – analysis using integrated backscatter IVUS (ELAN Study). Circ J 2011;75:633-41.; Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the ESC and the EACTS Developed with the special contribution of the EAPCI. Eur Heart J 2010;31: 2501-55.; https://www.rpcardio.com/jour/article/view/215Test

  6. 6
  7. 7
  8. 8
  9. 9
    دورية أكاديمية

    وصف الملف: application/pdf

    العلاقة: Scopus; Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS) / Р. Г. Оганов, В. В. Кухарчук, Г. П. Арутюнов [и др.] //Кардиоваскулярная терапия и профилактика. – 2012. - 11(4). – с. 70-78.; http://elib.usma.ru/handle/usma/6956Test

  10. 10